Thus, dual-targeting of TFEB and NRF2 offers a promising therapeutic strategy for AMD, and future research should focus on elucidating their interplay while advancing retina-specific delivery systems, stage-tailored interventions, and robust preclinical models to unlock their full clinical potential. Here, NFE2L2 is linked to age-related macular degeneration.